newsfilter
← Latest News
GlobeNewswire·

Vigil Neuroscience Highlights 2024 Corporate Achievements and Upcoming 2025 Milestones

– On track to report data from Phase 1 clinical trial evaluating VG-3927 for the treatment of Alzheimer's disease in 1Q 2025 – – Final analysis from IGNITE Phase 2 clinical trial evaluating iluzanebart in ALSP planned